PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 70 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,008,442 | -29.8% | 973,606 | +2.2% | 0.00% | – |
| Q2 2023 | $4,288,221 | -17.9% | 952,938 | +4.0% | 0.00% | – |
| Q1 2023 | $5,221,280 | -3.9% | 916,014 | +1.9% | 0.00% | – |
| Q4 2022 | $5,431,856 | -8.6% | 899,314 | +0.0% | 0.00% | – |
| Q3 2022 | $5,943,000 | +26.6% | 899,045 | 0.0% | 0.00% | – |
| Q2 2022 | $4,693,000 | -15.0% | 899,045 | +12.3% | 0.00% | – |
| Q1 2022 | $5,523,000 | -42.5% | 800,498 | +3.8% | 0.00% | – |
| Q4 2021 | $9,604,000 | -73.0% | 771,440 | -32.1% | 0.00% | -100.0% |
| Q3 2021 | $35,522,000 | +10.2% | 1,136,722 | +0.9% | 0.00% | 0.0% |
| Q2 2021 | $32,238,000 | -14.2% | 1,126,047 | +29.8% | 0.00% | 0.0% |
| Q1 2021 | $37,585,000 | -20.4% | 867,420 | +31.5% | 0.00% | 0.0% |
| Q4 2020 | $47,212,000 | +3381.7% | 659,845 | +1366.3% | 0.00% | – |
| Q3 2020 | $1,356,000 | – | 45,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $57,226,239 | 1.12% |
| Baker Brothers Advisors | 10,123,824 | $57,705,797 | 0.31% |
| Boxer Capital, LLC | 699,047 | $3,985 | 0.20% |
| GSA CAPITAL PARTNERS LLP | 47,614 | $271 | 0.03% |
| DENALI ADVISORS LLC | 8,200 | $46,740 | 0.02% |
| 683 Capital Management, LLC | 28,631 | $163,197 | 0.01% |
| Virtu Financial LLC | 11,201 | $64 | 0.01% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 2,273,894 | $12,961,196 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $210,609 | 0.01% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 84,667 | $482,602 | 0.00% |